The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Novel approaches to developing new antibiotics for bacterial infections
Open accessAbstract
Antibiotics are an essential part of modern medicine. The emergence of antibiotic‐resistant mutants among bacteria is seemingly inevitable, and results, within a few decades, in decreased efficacy and withdrawal of the antibiotic from widespread usage. The traditional answer to this problem has been to introduce new antibiotics that kill the resistant mutants. Unfortunately, after more than 50 years of success, the pharmaceutical industry is now producing too few antibiotics, particularly against Gram‐negative organisms, to replace antibiotics that are no longer effective for many types of infection. This paper reviews possible new ways to discover novel antibiotics. The genomics route has proven to be target rich, but has not led to the introduction of a marketed antibiotic as yet. Non‐culturable bacteria may be an alternative source of new antibiotics. Bacteriophages have been shown to be antibacterial in animals, and may find use in specific infectious diseases. Developing new antibiotics that target non‐multiplying bacteria is another approach that may lead to drugs that reduce the emergence of antibiotic resistance and increase patient compliance by shortening the duration of antibiotic therapy. These new discovery routes have given rise to compounds that are in preclinical development, but, with one exception, have not yet entered clinical trials. For the time being, the majority of new antibiotics that reach the marketplace are likely to be structural analogues of existing families of antibiotics or new compounds, both natural and non‐natural which are screened in a conventional way against live multiplying bacteria. British Journal of Pharmacology(2007)152, 1147–1154; doi:10.1038/sj.bjp.0707432; published online 20 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167 · cited 1×
“Biofilms, for example on indwelling catheters, are complex mixtures of bacteria, which contain both multiplying and non-multiplying bacteria (Costerton et al., 1999).”
BackgroundBacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“A particularly interesting finding is that lysins may be active against non-multiplying bacteria and biofilms (Balaban et al., 2004; Entenza et al., 2005).”
BackgroundDrugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 2×
“In certain situations, such as biofilms, other factors may be important for the destruction of non-multiplying bacteria, such as effective penetration of the antibiotic, or a huge local concentration of bacteria that require a high level of antibiotic, which cannot be achieved therapeutically (Smith and Brown, 2003; F…”
BackgroundTrends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Cited by
PHAST: A Fast Phage Search Tool
Zhou, Y., Liang, Y., Lynch, K. H., Dennis, J. J., & Wishart, D. S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr485 · Cited by 2,048
Acinetobacter baumannii: An emerging opportunistic pathogen
Howard, A., O’Donoghue, M., Feeney, A., & Sleator, R. D. (2012) · Virulence · doi:10.4161/viru.19700 · Cited by 837
Exogenous Alanine and/or Glucose plus Kanamycin Kills Antibiotic-Resistant Bacteria
Peng, B., Su, Y.-B., Li, H., Han, Y., Guo, C., Tian, Y.-M., & Peng, X.-X. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.008 · Cited by 481
The antibiotic resistance crisis, with a focus on the United States
Martens, E., & Demain, A. L. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.30 · Cited by 445
Microbial Biofilms and Chronic Wounds
Omar, A., Wright, J., Schultz, G., Burrell, R., & Nadworny, P. (2017) · Microorganisms · doi:10.3390/microorganisms5010009 · Cited by 348
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Targeting the “Cytokine Storm” for Therapeutic Benefit
D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00636-12 · Cited by 324
Significance and Biological Importance of Pyrimidine in the Microbial World
Sharma, V., Chitranshi, N., & Agarwal, A. K. (2014) · International Journal of Medicinal Chemistry · doi:10.1155/2014/202784 · Cited by 279
Annunziato, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235844 · Cited by 256
Yoo, J.-W., Nurhasni, H., Cao, J., Choi, M., Kim, I., Lee, B. L., & Jung, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s82199 · Cited by 131
“Considering that resistance against newly approved antibiotics develops within 2 years, 8 there is an urgent need for new generations of antibiotics to fight infections.”
Can literature analysis identify innovation drivers in drug discovery?
Agarwal, P., & Searls, D. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2973 · Cited by 100
Antibiotic research in the age of omics: from expression profiles to interspecies communication
Wecke, T., & Mascher, T. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr373 · Cited by 62
Metadata
- Authors
- Coates, A. R. M., & Hu, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-12
- Volume
- 152
- Issue
- 8
- Pages
- 1147-1154
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2151289717
- Cited by
- 218
- References
- 6
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.